1.800.332.2351
M-F 7am-7pm CST
Shop Now
About Us
Partner Benefits

Ortho Molecular Products Announces New Calocurb® Clinical Trial Results

calocurb family image

Newly published research further supports Calocurb® CLINICAL as a practitioner-guided solution for appetite, cravings and weight management support.

BARRINGTON, Ill. - [July 28, 2026] - Ortho Molecular Products announced the publication of the fourth human clinical trial evaluating Calocurb® and its active ingredient, Amarasate®, a patented New Zealand bitter hops extract developed to support appetite and craving control. In the newly published six-month study, participants using Calocurb achieved greater weight loss than placebo while preserving lean muscle mass.

The randomized, double-blind clinical trial undertaken by a research institute of the New Zealand government evaluated Calocurb® over 24 weeks with a three-month follow-up on all participants. Those who took Calocurb® experienced significantly greater reductions in body weight, body fat and visceral fat, and also maintained muscle mass, compared to the placebo group. Key results from Calocurb®'s fourth human clinical study include the following:

  • Calocurb® is clinically shown to improve body composition by reducing body fat without losing muscle mass
    • Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group
  • Over 6.5x greater reduction in body fat vs. placebo
    • Average body fat loss of 9.9 lbs (4.49 kg) vs. 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb® vs. placebo
  • 3.5x greater reduction in visceral fat vs. placebo
    • Average visceral fat loss of 5 in2 (32.5 cm2) vs. 1.4 in2 (9.1 cm2) lost after six months of consistent use of Calocurb® vs. placebo

As the exclusive US distribution partner for Calocurb® CLINICAL in the professional channel, Ortho Molecular Products brings this evidence-based, plant-derived appetite management solution to licensed practitioners seeking science-backed tools for metabolic health and patient support.

The study adds to a growing body of evidence supporting Amarasate®, which has now been evaluated in four human clinical studies.

Together with earlier acute studies showing a 30% reduction in hunger, 40% reduction in cravings and reduced calorie intake of 18%, the six-month data further supports Amarasate® as a fast-acting, plant-derived appetite management tool with longer-term relevance for practitioner-guided weight management.

Calocurb® CLINICAL delivers a 250 mg therapeutic dose of Amarasate® in a targeted-release capsule designed to activate bitter taste receptors in the small intestine and stimulate the body's natural release of satiety-related hormones, including GLP-1, CCK and PYY.

“This publication reinforces why we partnered with Calocurb®: practitioners need credible tools that help patients address hunger, food noise and cravings through mechanisms that work with the body,” said Nate Freeman, vice president of science and innovation at Ortho Molecular Products. “Calocurb® CLINICAL fits directly into our commitment to efficacy, practitioner guidance and better patient outcomes.”

For practitioners evaluating comprehensive approaches to weight management, metabolic health and long-term lifestyle support, the study provides clinically meaningful context for supporting appetite control without compromising body composition goals.

“We're proud to partner with Ortho Molecular Products to help expand practitioner access to a solution grounded in human clinical research,” said Sarah Kennedy, founder and CEO of Calocurb®. “The publication of our fourth clinical trial gives clinicians another important data point as they support patients seeking sustainable approaches to appetite control and metabolic wellness.”

Calocurb® CLINICAL is available exclusively through licensed health care practitioners. For more information, practitioners can contact Ortho Molecular Products directly or their local sales representative.

###

About Ortho Molecular Products

For nearly 40 years, Ortho Molecular Products has partnered exclusively with licensed health care practitioners to deliver evidence-based nutraceuticals that support individualized patient care. The company is committed to clinical efficacy, practitioner education and product quality from ingredient sourcing through finished product.

About Calocurb® CLINICAL

Calocurb® CLINICAL is a targeted, plant-based appetite and craving control supplement formulated for the professional channel. Its active ingredient, Amarasate®, is a patented bitter hops extract developed through more than a decade of research in New Zealand and evaluated in human clinical trials for its effects on weight loss, fat loss and muscle maintenance.

©  Ortho Molecular Products

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
In compliance with Health Plan Cost Transparency click here to access our health plan’s cost data files.